Abstract
Register of Controlled Trials (CENTRAL), and China National Knowledge Infrastructure (CNKI). CNKI is an electronic platform created to integrate significant Chinese knowledgebased information resources. A combined text and subject heading terms (Mesh and EMTree) related to the observed use of cardiovascular medication (aspirin, beta-blockers, ACE-inhibitors <ACE-I>, statin, and nitrates) among adults in China were used (S1 Table) .
Articles were excluded from the review if: i) published in a language other than English or Chinese; ii) focused on primary care of MI only; iii) reported medication use for CVD but not specified for MI; iv) focused on cardiovascular medication use before or during hospital admission; v) performed outside of China or conducted in non-Chinese populations; vi) performed as randomized control trials on cardiovascular medication evaluation; vii) animal studies, study protocols, bimolecular studies, case reports, non-peer reviewed published reports of proceedings, and reviews (S1 Table) .
In the current review, studies reporting broadly on Acute Coronary Syndromes (ACS) were included. Apart from explicit clinical diagnosis, current guidelines and evidence indicate no difference for medical treatment and prevention level for both ACS and MI. [10] [11] [12] Furthermore, angiotensin receptor blockers (ARB) are clinical recommended when patients do not tolerate ACE-Is. [6, 11, 12] Therefore, studies reporting ACE-I/ARB were also included. ACE-I/ ARB was considered as an independent medication category and hence analyzed separately.
Selection process
Search results were downloaded into Refwork for Pubmed, EMBASE, and CENTRAL hits and EndnoteX7 for CNKI. Two independent reviewers (MZ and XW) screened all articles by title and abstract for inclusion and exclusion criteria. Duplicate records were automatically removed by reference management software. Any disagreements between the two reviewers on paper selection were discussed by explicit selection rules, and the full-text reviewed if necessary. For eligible articles, the full text of eligible articles were retrieved and assessed by two reviewers (MZ and XW) following processes.
Data extraction
A standardized data extraction form was designed to capture study characteristics, participants' characteristics, and outcome measures. Extracted items included were: sample size, performed geographic area, year of survey, participation rate, mean age, proportion of women, known history (coronary heart disease, MI, hypertension, dyslipidaemia, and diabetes), and prevalence of cardiovascular medication (aspirin, beta-blockers, statins, ACE-Is, ACE-I/ARB, and nitrates) in each study. If multiple publications were derived from one study, all unique data were extracted and combined directly into a single data extraction form. If the reported study characteristics differed from publication to publication in the same study, the publication with most explicit participants' characteristics and outcome measures was extracted and others were excluded. When results were published multiple times, the data was used only once. Extraction was done by a single reviewer. Lack of clarity during the extraction process was resolved by consulting the second reviewer (XW).
Quality assessment
To appraise the risk of bias of individual studies we used a tool developed by Li et al (S2 Table) [13] . The tool consists of five items that assess the quality of the study design, study population, participation rate, participants' characteristics, and outcome. Presence of bias was assessed by scoring (low risk = 2, moderate risk = 1, high risk = 0) each of the five items. Studies with a summative score below 6 were excluded from this review (S2 Table) .
Data analysis
The prevalence of cardioprotective medication use was defined as the number of MI patients using the medication of interest divided by the total number of MI patients and displayed as proportions. Heterogeneity was presented among included studies as the I 2 statistics>75%
and P value of Q statisitcs<0.05. Hence, a random-effects model to meta-analyse the logittransformed proportions to obtain a pooled estimate together with a 95% confidence interval (CI) was used. The model took into account the precision by which this proportion has been estimated in each study using the binomial distribution and incorporating any additional variability beyond chance that exists between studies.
To identifly factors associated with the use of cardiovascular medication, we added several study characteristics as covariates to our random effect meta-regression models. The following characteristics extracted from individual studies were examined independently: year of survey, mean age, proportion of women and geographic area. The meta-regression models, showing statistically significant association between specific study characteristics and cardioprotective medication use, were then used to estimate the prevalence of cardiovascular medication use for 1995 and 2015. All tests were two tailed with statistical significance at 0.05 level.
Statistical analyses were performed by using R 'metafor' package. [14] Results
Study selection
The initial search resulted in 13,940 potentially relevant articles, of which 13,411 were excluded by screening title/abstract and 490 by full-text review (Fig 1) . The main reasons for exclusion included: non-observational studies; non-English/Chinese studies; non-Chinese participants; non-MI participants; no data on the use of cardiovascular medication. Details are provided in the flow chart (Fig 1) . After risk of bias assessment, 35 articles were selected, of which three were written in English. Detailed information on the basis assessment for the individual studies is provided in S2 Table. Study characteristics Prevalence of cardiovascular medication use Temporal trends in prevalence of cardiovascular medication use Fig 7 illustrates year-specific prevalence of individual cardiovascular medication use from 1995 to 2015. The meta-regression of the year over logit-transformed prevalence showed a trend towards an increasing prevalence of beta-blocker use from 1995 to 2015 with a slope of 0.1 (p<0.0001). This gives an estimate of 78% for beta-blockers use in 2015, compared to 32% in 1995. A similar increasing trend was demonstrated for statins use, even when the first available study was from 1999 (slope = 0.26; P = 0.0004). Accordingly, the estimated statins use was 17% in 1995 and 91% in 2015. In contrast, the estimated prevalence of nitrates use dropped from 95.5% in 1995 to 59.3% in 2015. There was no significant association between the year of survey and prevalence of aspirin, ACE-Is, and ACE-I/ARB use.
Other demographic and geographic factors
Among studies that reported either demographic (the mean age and proportions of women) or geographic characteristics, there was little evidence for an association between these study characteristics and the logit-transformed prevalence of cardiovascular medications, except for aspirin (S4 Table) . Aspirin use showed significant association with mean age (slope: 0.26, P = 0.02), indicating that elderly patients with previous MI are more likely to take aspirin for their medical conditions. 
Discussion
Cardiovascular medications are considerably underused for secondary in China, even though a pronounced increase in beta-blocker and statin use has been noticed over the period from 1995 to 2015.
In the current review, the reported prevalence of cardiovascular medications in China varied widely across studies. The largest variation on prevalence of these six cardiovascular medications was reported for statin use, ranging from low (14.6%) [16] to high (99.1%) [29] , among included studies. The prevalence variations of other cardiovascular medication use are also notable in this review. The lowest prevalence for beta-blockers, ACE-Is, ACE-I/ARB, and nitrates was 27% [15] , 31.5% [15] , 35.3% [25] , and 47.3% [32] in comparison to the highest prevalence with 93.6% [29] , 67.8% [21], 95% [29] , and 96.8%19 reported, respectively. Aspirin showed the least variation for reported prevalence, varying from 65.7% [36] to 99.4% [18] .
To investigate the determinants of these variations in prevalence of cardiovascular medication use, meta-regression models were performed with specific study characteristics as covariates in current review. In line with previous findings [50, 51] , elderly patients with previous MI were observed to be more likely to take aspirin. Aspirin is not only used to prevent cardiovascular events but also applied for other medical conditions [52] and thus, older patients may be more likely to report use of aspirin. Although several studies have demonstrated differences in use of cardiovascular medications by age, sex, or geographic area [51, [53] [54] [55] , no other significant associations between demographic and geographic characteristics and cardiovascular medication use were observed in the current study. However, it should be noted that Chinese national guidelines recommend cardiovascular medications as part of secondary prevention strategy for all MI patients in daily practice irrespective of age, sex, or geographic area. [6] The observed trends of cardiovascular medication use are likely to be related to recent changes of the healthcare system, insurance coverage, and published national guidelines in China. [1, 6, 56] After the Chinese government implemented its healthcare system reform policies in 2009 [1] and increased its insurance coverage up to 95.7% by 2011 [57] , the availability of health-care access and affordability of medication prescription have improved considerably in China. [5, 58] Introduction and regular updates of the Chinese national guidelines of MI were additionally used to complement this renewed healthcare system to standardize physician's daily practice and improve quality of care. [6, 10] Furthermore, the Chinese National Essential Medicine List (EML) was developed and is expected to be fully available by 2020 to support rational medication use and improve the access to safe and effective essential medication [5, 21] . Already, a notable reduction of inappropriate drug prescriptions has been observed after EML implementation. [59] Reflecting these achievements, the use of guideline-recommended cardiovascular medications is expected to gradually increase in China.
Despite material healthcare improvements in China, it is also important to realize that the current review shows that cardiovascular medication is not on par with guideline recommendations indicating insufficient guideline implementation in daily practice. Studies have shown Chinese physicians to have a low awareness of up-to-date guidelines [60, 61] , affecting clinical decisions in spite of guideline recommendations [61] [62] [63] . Moreover, lack of knowledge among patients about their disease or the necessity of adequate treatment could also have contributed to low use of cardiovascular medications. [60] Notwithstanding improvements of the healthcare system and wider insurance coverage in China, CVD patients still face high personal expenditures on CVD care [64] . The Chinese national Bureau of Statistics showed private (out-of-pocket) expenditures to increase approximately by 10% per year [65] , despite 20% annual increase on healthcare budget from government. Thus given high out-of-pocket expenditures, Chinese patients may face considerable financial hardship after a MI event, which may hamper their ability to manage their medical conditions, seek proper medical advice, or adhere to prescribed medications [56, 66, 67] , calling an increased focus on the provision of accessible and to affordable healthcare service for the Chinese population.
Inadequate guideline-recommended cardiovascular medication use has been properly reported for other low-and middle-countries. [68, 69] The PURE study, a large international observational study in 30 countries, indicated a low use of the antiplatelet, beta-blockers, ACE-I/ARB and statins in South Asia (11.6%, 11.9%, 6.4%, and 4.8%), Malaysia (14.9%, 12.5%, 12.8%, and 15.9%), and Africa (3.4%, 1.9%, 6.8%, and 1.4%) and demonstrated the challenges of affordability and availability of these medications. [67, 68, 70] Generally, these medications were observed to be more commonly available and affordable in high-income countries with more advanced healthcare systems and better quality of care in daily practice [67] , resulting in higher reported cardiovascular medication use in these countries. [71, 72] Unless both healthcare system and insurance coverage are improved towards wider availability and affordability of these medications, the use of guideline-recommended cardiovascular medication is likely to remain low in many low-and middle-income countries.
There are several limitations to this review. First, most published studies in China are more likely to come from centers with more advanced healthcare service and better facilities. In contrast, prevalence of cardiovascular medication is rarely reported and published in centers with limited resources, especially in rural areas. In the current review, comparative data collected from rural area is lacking and thus, due to limited availability of published data, we could not perform detailed stratified analysis of cardiovascular medication use by urban and rural area. Findings from these included, generally more urban, studies of our review may thus not be representative for the whole country. This is a source of bias potentially overestimating the prevalence of cardiovascular medication use in China. A representative study with a comprehensive investigation on the prevalence of cardiovascular medication in China is thus warranted. Secondly, this meta-analytic study collected its data from a large number of published observational studies with diverse study designs and population characteristics resulting in substantial study heterogeneity (S5 Table) and indicating potentially adverse effects on the stability and interpretability of the pooled prevalence estimates. Variability of the reported prevalence reflects cardiovascular medication use in daily practice. Application of random effect models and analyzed associated covariates explain these observed variations, although not individual patient level, limiting the potential of the current review to disclose associations between patient characteristics and cardiovascular medication use.
The strength of this review lies in its use of four databases to systematically search for articles including a large Chinese database. CNKI was used as a supplementary searching platform to incorporate both English and Chinese literature and to minimize limited access to Chinese publications from English language databases. Comprehensive Chinese searching terms were also used as part of our search strategy to cover literature published in China. Secondly, after validating all selected studies by a comprehensive quality assessment tool, meta-analysis and meta-regression models were performed to summarize the pooled estimates of cardiovascular medication use in China and assess its determinants. We observed significant year trends in prevalence of cardiovascular medication use for secondary prevention of MI over the last two decades, reflecting the rapid epidemiological changes in China. To our knowledge, this is the first review to investigate the trends of cardiovascular medication prevalence in China.
In summary, the current cardiovascular medication use in China is inadequate in comparison to guideline recommendations, although the reported use of these medications has increased over the last two decades. This should act as a wake-up call for policymakers and healthcare bodies to forcefully restructure and implement secondary prevention strategies, educate health professionals to update clinical knowledge and follow current guidelines recommendations for treatment, and create awareness among patients about health status and the benefits of appropriate medication. Table. Quality of risk bias assessment. Data collection and statistical analysis method were assessed in study design. Studies with summed score of 6 or below was considered as bad quality and excluded from this systematic review and meta-analysis. (DOCX) 
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